Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stock Plummets 14 Percent on Unreliable Q2 Results

NEW YORK, Nov. 17 (GenomeWeb News) - Shares in Ciphergen tumbled 13.87 percent, or $.24, to $1.49 in mid-afternoon trading after Ciphergen yesterday said that its second-quarter earnings report should "no longer be relied upon."

 

As GenomeWeb News reported earlier this morning, an audit committee appointed by Ciphergen said second-quarter earnings should be restated to correct the $500,000 in revenue that had apparently been improperly recorded from that period.

 

Ciphergen stock has had a rough week. Earlier this week, Nasdaq removed Ciphergen from its Nasdaq Biotechnology Index. The exchange also said that the company's common stock will be delisted from the Nasdaq National Market as of Nov. 25 for failing to file its third-quarter earnings report.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.